Suppr超能文献

在急性白血病的异基因造血细胞移植中,低强度预处理后的生存率并不低于标准高剂量预处理后的生存率。

Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias.

作者信息

Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P, Rosen O, Wernecke K-D, Dörken B, Arnold R

机构信息

Department of Haematology and Oncology, Campus Virchow-Klinikum, Charité - University Medicine Berlin, Berlin, Germany.

出版信息

Bone Marrow Transplant. 2005 Oct;36(8):683-9. doi: 10.1038/sj.bmt.1705123.

Abstract

To assess the role of allogeneic stem cell transplantation (SCT) after reduced-intensity conditioning (RIC) in acute leukaemias, we retrospectively compared 25 patients with acute lymphoblastic leukaemia or acute myelogenous leukaemia after RIC to a historical group of 50 matched controls after high-dose conditioning. Engraftment, acute GvHD and severe infections were comparable in both groups. During the observation period, 1/25 patients (4%) after RIC and 14/50 (28%) after standard SCT died due to transplant-related causes; cumulative nonrelapse mortality (NRM) was 4% after RIC and 24% after standard SCT (P=0.029). In total, 15/25 patients (60%) relapsed after RIC and 20/50 (40%) after standard SCT; probability of disease-free survival (DFS) at 3 years was 43% after RIC and 49% after standard SCT (NS). Overall survival (OS) was 40% after RIC and 37% after standard SCT (NS). Stage of disease, cytogenetic risk profile, acute and chronic GvHD, chimerism status at day 90 and severe infections after transplantation were risk factors with significant impact on DFS and/or OS. In retrospective analysis, patients with acute leukaemias who receive RIC because of contraindications against standard SCT have a comparable outcome to standard SCT, but the higher relapse rate warrants further studies.

摘要

为评估急性白血病患者在减低剂量预处理(RIC)后接受异基因干细胞移植(SCT)的作用,我们回顾性比较了25例急性淋巴细胞白血病或急性髓细胞白血病患者在RIC后的情况与50例经高剂量预处理的匹配历史对照患者。两组的植入、急性移植物抗宿主病(GvHD)和严重感染情况相当。在观察期内,RIC后25例患者中有1例(4%)、标准SCT后50例患者中有14例(28%)死于移植相关原因;RIC后的累积非复发死亡率(NRM)为4%,标准SCT后为24%(P=0.029)。总共有25例患者中有15例(60%)在RIC后复发,50例中有20例(40%)在标准SCT后复发;RIC后3年无病生存(DFS)概率为43%,标准SCT后为49%(无显著性差异)。RIC后的总生存(OS)率为40%,标准SCT后为37%(无显著性差异)。疾病分期、细胞遗传学风险特征、急性和慢性GvHD、移植后90天的嵌合状态以及严重感染是对DFS和/或OS有显著影响的危险因素。在回顾性分析中,因标准SCT存在禁忌证而接受RIC的急性白血病患者的结局与标准SCT相当,但较高的复发率值得进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验